- Home
- SXTC vs NRXS Comparison
SXTC vs NRXS Comparison
Compare SXTC & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SXTC | NRXS |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.9M | 78.9M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SXTC | NRXS |
|---|---|---|
| Price | $3.30 | $6.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 55.0M | 90.5K |
| Earning Date | 08-19-2019 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.03 | $2.21 |
| 52 Week High | $6.98 | $9.33 |
Technical Indicators
Market Signals| Indicator | SXTC | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 69.11 | 42.02 |
| Support Level | $1.95 | $5.77 |
| Resistance Level | $6.40 | $7.62 |
| Average True Range (ATR) | 0.17 | 0.49 |
| MACD | 0.42 | -0.02 |
| Stochastic Oscillator | 76.61 | 47.95 |
Price Performance
Historical ComparisonAbout SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly TCMP (Directed-oral TCMP and After-soaking TCMP), which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).